Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 200 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
Latest News
Summary
- Livtencity (maribavir) is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet.
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- In kidney transplant recipients (KTRs), prophylaxis significantly reduced CMV infection (pOR 0.33; 95% CI: 0.19, 0.57) and CMV disease (pOR 0.27; 95% CI: 0.19, 0.39) compared to no prophylaxis but was associated with higher rates of late CMV infection and hematological adverse events, including leukopenia (pOR 2.93; 95% CI: 1.22, 7.04).
- Preemptive therapy (PET) in KTRs resulted in lower rates of CMV disease (pOR 0.29; 95% CI: 0.11, 0.77) and reduced medical costs compared to no PET, with fewer hematological adverse events compared to prophylaxis.
- Maribavir demonstrated effectiveness in managing refractory or resistant HCMV infections in transplant recipients, whereas Letermovir was effective in preventing CMV in hematopoietic stem cell transplant recipients.
- There is no specific safety information available regarding Maribavir in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Livtencity (maribavir) Prescribing Information. | 2024 | Takeda Pharmaceuticals America Inc., Lexington, MA |
Health Technology Assessments
Document Title | Year | Source |
---|---|---|
Clinical and pharmacoeconomic combined report. | 2023 | CADTH |
Assessment report: Livtencity. | 2022 | EMA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Anti-CMV therapy, what next? A systematic review. | 2023 | Frontiers in Microbiology |
Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: a systematic review of randomized controlled trials. | 2021 | Transplantation Reviews |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). | 2019 | The Lancet: Infectious Diseases |